To examine the relationship between past use of oral contraceptives (OCs) and development of systemic lupus erythematosus (SLE).
Methods
Prospective cohort study of 121,645 women who were followed up every 2 years between 1976 and 1990 as part of the Nurses' Health Study. Women were classified as never users or past users of OCs based on self-report. Incidence of SLE was defined by 1) strict American College of Rheumatology (ACR) classification criteria (> or = 4 ACR criteria), 2) > or = 4 ACR criteria and any physician's diagnosis, 3) > or = 4 ACR criteria and diagnosis by an ACR-certified rheumatologist, 4) > or = 3 ACR criteria, or 5) diagnosis by a physician even if the patient did not meet the ACR criteria.
Results
Compared with never users of OCs, and after adjusting for age and ever use of postmenopausal hormones, the relative risk (95% confidence interval [95% CI]) for the incidence of SLE in the women who had definite cases of SLE (> or = 4 ACR criteria) (n = 99) was 1.4 (0.9-2.1) for past users of OCs. Using the most stringent case definition (ACR criteria plus a diagnosis of SLE by an ACR member) (n = 58), the relative risk for past users compared with never users was 1.9 (95% CI 1.1-3.3). No relationship was observed between duration of OC use or time since first use and the risk of developing SLE.
Conclusion
Past use of OCs was associated with a slightly increased risk of developing SLE. The decision to use hormonal contraception must be individualized, but the small absolute risk observed for the development of SLE in white women should not be a dominant factor in the decision.
oral contraceptives systemic lupus risk, birth control pills autoimmune disease, lupus erythematosus hormonal contraception, contraceptive use sle development, nurses health study lupus, past oral contraceptive use lupus risk, hormonal contraception autoimmune disorders, sle incidence birth control pills, contraceptive side effects lupus, informed consent oral contraceptives lupus
Cite this article
Sanchez-Guerrero, J., Karlson, E. W., Liang, M. H., Hunter, D. J., Speizer, F. E., & Colditz, G. A. (1997). Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. *Arthritis and rheumatism*, *40*(5), 804-808. https://doi.org/10.1002/art.1780400505
Sanchez-Guerrero J, Karlson EW, Liang MH, Hunter DJ, Speizer FE, Colditz GA. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum. 1997;40(5):804-808. doi:10.1002/art.1780400505
Sanchez-Guerrero, J., et al. "Past use of oral contraceptives and the risk of developing systemic lupus erythematosus." *Arthritis and rheumatism*, vol. 40, no. 5, 1997, pp. 804-808.
Boyko EJ et al., 1994American Journal of Epidemiology
Research on inflammatory bowel disease risk among oral contraceptive users has reached conflicting conclusions. This population-based case-control study evaluated the effects of oral contraceptive use...
Contraception/Comparison > Side Effects > Hormonal ContraceptionContraception/Comparison > FABM vs Hormonal > Side Effects
Yonis H et al., 2025
Open Access
BMJ (Clinical Research Ed.)
Objective: To evaluate the association between contemporary hormonal contraceptive use and the risk of incident ischaemic stroke and myocardial infarction.
Design: Real-world, nationwide, prospective ...
Contraception/Comparison > Side Effects > Hormonal ContraceptionContraception/Comparison > FABM vs Hormonal > Side EffectsGeneral OB/GYN > Epidemiology > Prevalence
Background: The combined hormonal contraceptive (CHC) with ethinylestradiol and progestins is the most widely used contraceptive method among young women and is used by millions worldwide. However, un...
Contraception/Comparison > Side Effects > Hormonal ContraceptionContraception/Comparison > FABM vs Hormonal > Side EffectsGeneral OB/GYN > Epidemiology > Prevalence
Huang Y et al., 2024
Open Access
Frontiers in Endocrinology
Background: Premature ovarian insufficiency/failure (POI/POF) is a significant issue for women of reproductive age. Anti-Müllerian hormone (AMH) is a potential biomarker of ovarian reserve, but its cl...
Contraception/Comparison > FABM vs Hormonal > Side EffectsContraception/Comparison > Side Effects > Hormonal ContraceptionGeneral OB/GYN > Epidemiology > Prevalence